IPM Take
CIDP is often described clinically, but patients live it functionally: walking less, gripping less, feeling less, depending more. The current treatment world still leans heavily on immunoglobulin pathways, infusion logistics and repeated long-term care. Empasiprubart is not approved, and EMNERGIZE has no efficacy result yet. But the trial matters because it asks whether a more targeted immune strategy can reduce disability without simply adding another complicated layer to care.
Executive Summary
NeurologyLive reported that the design of the ongoing Phase 3 EMNERGIZE trial was detailed at the 2026 Peripheral Nerve Society Annual Meeting. EMNERGIZE is evaluating empasiprubart, an investigational complement C2 inhibitor, in adults with active chronic inflammatory demyelinating polyneuropathy. The global randomized, double-blind, placebo-controlled study is designed to enrol approximately 160 adults with CIDP. Participants are randomized 2:1 to empasiprubart or placebo during a 24-week double-blind period, followed by extension and safety follow-up. The primary endpoint is the proportion of patients achieving at least a 1-point improvement from baseline on the adjusted INCAT disability score at week 24
Why it matters
- Patients: CIDP treatment is not only about immune control. It is about walking, grip, fatigue, independence and the burden of repeated therapy.
- Neurologists: The trial tests whether complement C2 inhibition can become a clinically meaningful option in active CIDP, including selected variants.
- Payers and regulators: If successful, the access debate will focus on functional benefit, infusion burden, long-term safety and positioning against established therapies.
CIDP is the kind of disease that can quietly shrink a life.
A person walks less because the legs feel unreliable. Stairs become a calculation. Hands lose strength. Sensation changes. Fatigue enters daily planning. Treatment may help, but treatment itself can become a burden: infusions, appointments, relapses, partial response and uncertainty.
That is the access problem behind EMNERGIZE.
Empasiprubart is an investigational antibody targeting complement component C2. The logic is upstream: block classical and lectin complement activation, while leaving the alternative pathway more intact. In CIDP, where immune-mediated nerve injury drives weakness and disability, that is a plausible strategy. But plausibility is not proof.
The Phase 3 EMNERGIZE trial is designed to test whether the mechanism translates into function. The trial focuses on disability improvement, supported by measures of overall disability, strength, grip and mobility. That matters because CIDP patients do not need a cleaner immune theory. They need measurable recovery or stability.
For IPM, this article should be framed as a treatment-burden story. The future of neuroimmunology is not only new targets. It is whether those targets reduce the practical weight of care. A therapy that works but remains hard to access, hard to sustain or hard to reimburse does not fully solve the last mile.
CIDP needs more options. But the field should judge them by what patients can do, not only by what pathways they block.
